Press release
Renal Cancer Drugs Market Report 2022: By Key Players, Trends, Size, Share and Forecast 2022-2028
The global renal cancer drug market is projected to grow at a significant CAGR during the forecast period. The market is segmented on the basis of cancer type, drug class, and therapeutic class. Based on the cancer type, the market is segmented into renal cancer carcinoma, clear cell renal cell carcinoma, non-clear renal cell carcinoma, and others. Based on the drug class, the market has been sectioned as angiogenesis inhibitors, monoclonal antibodies, mTOR inhibitors, and cytokine immunotherapy (IL-2). Based on the therapeutic class, the global renal cancer drug market is segmented into targeted therapy, immunotherapy, and chemotherapy.A full report of Renal Cancer Drugs Market is available at: https://www.omrglobal.com/industry-reports/renal-cancer-drugs-market
Targeted cancer therapies involve the usage of drugs that can block the growth and spread of the cancer cells by interfering with specific molecules that are responsible for the progression, and spread of cancer cells. Some of the drugs available for the targeted therapy include Sunitinib (Sutent), Sorafenib (Nexavar), Pazopanib (Votrient), Cabozantinib (Cabometyx), Lenvatinib (Lenvima), Bevacizumab (Avastin), Axitinib (Inlyta) among others. Targeted cancer therapies are often termed as molecularly targeted drugs, molecularly targeted therapies, precision medicines, or other similar names. Targeted drugs are especially crucial in diseases, where chemo has not been very useful. They work by targeting specific genes or proteins. These genes and proteins are found in cancer cells or cells responsible for the growth of cancer, such as blood vessel cells.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/renal-cancer-drugs-market
Immunotherapy treatment to cure renal cancer takes leverage of an individual's immune system to kill the cancer cells. Some of the drugs available for the Immunotherapy includes PD-1 inhibitors such as Pembrolizumab (Keytruda) and Nivolumab (Opdivo), PD-L1 inhibitors such as Avelumab (Bavencio), CTLA-4 inhibitors such as Ipilimumab (Yervoy), among others. Patients who are provided active immunotherapy treatment are treated with products that stimulate their immune system. Their immune system cells are made for recognizing an abnormal component in the cancer cells. These immune system cells or antibodies selectively kill those abnormal components. Cancer vaccine and immune checkpoint inhibitors are the two main types of immunotherapy.
Chemotherapy uses anti-cancer drugs injected into a vein or orally. Chemotherapy treatment is extremely effective for cancer that has spread to other organs (metastatic). Chemotherapy treatment has increased life expectancy in patients with cancer. Several drugs used for the treatment of renal cancer include cisplatin, 5-fluorouracil (5-FU), and gemcitabine. The side effects associated with chemotherapy depend on the type and dosage of drugs given and how long it has been taken. Common side effects include hair loss, mouth sores, loss of appetite, nausea, diarrhea.
The rising preference for novel immunotherapies and immune-oncologic agents will increase the use and the adoption of targeted therapies to specific patient subpopulations. Programmed death-1 (PD-1) inhibitors tend to displace TKIs and mTOR inhibitors as the standard of care in first-and second-lineRCC settings. Combination regimens, specifically PD-1 inhibitors will be introduced in the first-line setting for targeting major unmet needs, such as overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life. This, in turn, tends to drive the growth of the global renal cancer drug industry.
Global Renal Cancer Drugs Market - Segmentation
By Cancer Type
• Renal Cancer Carcinoma
• Clear Cell Renal Cell Carcinoma
• Non-Clear Renal Cell Carcinoma
• Others
By Drug Class
• Angiogenesis Inhibitors
• Monoclonal Antibodies
• mTOR Inhibitors
• Cytokine Immunotherapy (IL-2)
By Therapeutic Class
• Targeted Therapy
• Immunotherapy
• Chemotherapy
Renal Cancer Drugs Market- Segment by Region
North America
• United States
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
Company Profiles
• Active Biotech AB
• Amgen Inc.
• Aravive, Inc.
• Argos Therapeutics Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Cipla Ltd.
• Eisai Co., Ltd.
• Exelixis, Inc.
• Genentech, Inc.
• GlaxoSmithKline Plc
• Myriad Genetics Inc.
• NanoString Technologies Inc.
• NeoGenomics Laboratories Inc.
• Novartis International AG
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cancer Drugs Market Report 2022: By Key Players, Trends, Size, Share and Forecast 2022-2028 here
News-ID: 2618592 • Views: …
More Releases from Orion Market Research

Infrastructure as Code (IaC) Service Market Size Analysis, Competitive Insights, …
Infrastructure as Code (IaC) Service Market was valued at approximately USD 0.932 billion, and it's projected to expand to around USD 7.509 billion by 2033, achieving a robust CAGR of 23.2% from 2024 to 2033.
Infrastructure as Code (IaC) Service Market Overview
The Infrastructure as Code (IaC) Service Market is experiencing remarkable expansion, fueled by the escalating need for scalable, automated infrastructure deployment across cloud and enterprise environments. In 2023, the market…

Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market : A Guide to …
Ultra High‐Performance Liquid Chromatography (UHPLC) Columns Market is estimated to be valued at USD 2.5 billion, and is projected to grow to approximately USD 4.8 billion by 2033, representing a compound annual growth rate (CAGR) of about 7.8% from 2024 to 2033.
Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market Overview
The UHPLC columns market is on a strong growth trajectory, fueled by increasing demand for rapid, high-resolution analytical techniques across pharmaceuticals, biotechnology,…

Property Management Service Market Rising Demand and Growth Forecast Through 203 …
Property Management Service Market was valued at approximately USD 17.3 billion. It is anticipated to reach around USD 32.0 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2033.
Property Management Service Market Overview
The Property Management Service Market is witnessing steady growth due to increasing urbanization, rising investments in real estate, and a growing demand for outsourced property management solutions. Property owners are increasingly…

5G Chipset Market Set to Witness Significant Growth by 2033 | Apple Inc., HiSili …
The global 5G chipset market was valued at USD 33.75 billion in 2024 and is projected to reach USD 502.66 billion by 2033, growing at a compound annual growth rate (CAGR) of 35% from 2025 to 2033.
5G Chipset Market Overview
The 5G chipset market is experiencing rapid growth, driven by the global rollout of 5G networks and the increasing demand for high-speed, low-latency connectivity across various applications, including smartphones, IoT…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…